Cross-Reacting Material 197, a Specific Inhibitor of HB-EGF, and Its Anticancer Effects

M. Tanhapour, A. Golestani, A. Vaisi-Raygani, M. Aminian
{"title":"Cross-Reacting Material 197, a Specific Inhibitor of HB-EGF, and Its Anticancer Effects","authors":"M. Tanhapour, A. Golestani, A. Vaisi-Raygani, M. Aminian","doi":"10.18502/bccr.v13i1.8828","DOIUrl":null,"url":null,"abstract":"Genetic heterogeneity and metastasis remain the most challenging aspects of cancer treatment.Recent studies have introduced a mutant of diphtheria toxin,cross-reacting material197 (CRM197), as a new promising biological anticancer drug to improve cancer therapy in patients previously resistant to chemotherapy. Weak toxicity of CRM197accounts forthe stimulation ofcell apoptosis and the antitumor effect. Increasing evidence has indicated that the expression of heparin-binding epidermal growth factor-like (HB-EGF) growth factorincreases in most cancer cells, and CRM197 is its specific inhibitor.This study has focused on the structure, properties, and anticancer activity of CRM197.","PeriodicalId":8706,"journal":{"name":"Basic & Clinical Cancer Research","volume":"21 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-02-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Basic & Clinical Cancer Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18502/bccr.v13i1.8828","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Genetic heterogeneity and metastasis remain the most challenging aspects of cancer treatment.Recent studies have introduced a mutant of diphtheria toxin,cross-reacting material197 (CRM197), as a new promising biological anticancer drug to improve cancer therapy in patients previously resistant to chemotherapy. Weak toxicity of CRM197accounts forthe stimulation ofcell apoptosis and the antitumor effect. Increasing evidence has indicated that the expression of heparin-binding epidermal growth factor-like (HB-EGF) growth factorincreases in most cancer cells, and CRM197 is its specific inhibitor.This study has focused on the structure, properties, and anticancer activity of CRM197.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
HB-EGF特异性抑制剂-交叉反应物质197及其抗癌作用
遗传异质性和转移仍然是癌症治疗中最具挑战性的方面。最近的研究介绍了白喉毒素的一种突变体,交叉反应物质197 (CRM197),作为一种新的有前景的生物抗癌药物,可以改善以前对化疗耐药的癌症治疗。crm197的弱毒性是其刺激细胞凋亡和抗肿瘤作用的主要原因。越来越多的证据表明,肝素结合的表皮生长因子样(HB-EGF)生长因子在大多数癌细胞中表达增加,而CRM197是其特异性抑制剂。本研究主要对CRM197的结构、性质和抗癌活性进行了研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
16
审稿时长
12 weeks
期刊最新文献
The Effect of Ursodeoxycholic acid and N-acetyl cysteine on Lymphoblast Viability Cross-Reacting Material 197, a Specific Inhibitor of HB-EGF, and Its Anticancer Effects Chronic Myeloid Leukemia in a Young Man with Unusual Presentation of Weight Loss, Bone Pain, and Abdominal Pain Effects of Gold Nanoparticles on Proton Therapy for Breast Cancer Cancer has an Independent Association with Death in Hospitalized Patients with COVID-19: A Single-center Study in Iran
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1